Author:
Rashid Farzana,Lichtenstein Gary R.
Reference88 articles.
1. Simponi prescribing information:
http://www.simponi.com/shared/product/simponi/prescribing-information.pdf
.
2. Sandborn WJ, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109.
3. Lowenberg M, D’Haens G. Novel targets for inflammatory bowel disease therapeutics. Curr Gastroenterol Rep. 2013;13(2):311.
4. Hutas G. Golimumab, a fully human monoclonal antibody against TNFalpha. Curr Opin Mol Ther. 2008;10(4):393–406.
5. Perrier C, Rutgeerts P. New drug therapies on the horizon for IBD. Dig Dis. 2013;30 Suppl 1:100–5.